REGENXBIO Inc. (RGNX) Financials
RGNX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 574.0 million | 262.2 million |
2023-09-30 | 633.8 million | 270.7 million |
2023-06-30 | 682.5 million | 276.6 million |
2023-03-31 | 747.8 million | 282.7 million |
RGNX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -41.9 million | 8.3 million |
2023-09-30 | -50.8 million | 10.2 million |
2023-06-30 | -49.9 million | 10.5 million |
2023-03-31 | -85.7 million | 11.2 million |
RGNX Net Income
No data available :(
RGNX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 275.3 million | - | 89.3 million |
2023-09-30 | 301.9 million | - | 90.7 million |
2023-06-30 | 320.1 million | - | 91.6 million |
2023-03-31 | 331.8 million | - | 93.3 million |
RGNX Shares Outstanding
RGNX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 1.1 million | 55.7 million | 19.1 million | - |
2023-09-30 | 1.4 million | 58.2 million | 23.1 million | - |
2023-06-30 | 2.6 million | 59.9 million | 23.7 million | - |
2023-03-31 | 4.8 million | 58.5 million | 22.6 million | - |
RGNX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 22.2 million | 11.2 million |
2023-09-30 | 28.9 million | 12.4 million |
2023-06-30 | 20.0 million | 9.5 million |
2023-03-31 | 19.1 million | 4.1 million |
RGNX
Price: $16.19
52 week price:
Earnings Per Share: -6.02 USD
P/E Ratio: -2.43
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 295200
Ebitda: -20.6 millionMarket Capitalization: 939.2 million